Recruiting NCT06649305

A Prospective Multicenter Clinical Study： IntracOronary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes

— Observational Coronary Heart Disease (CHD) Diabetes (DM)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to: Registry conditions: Coronary Heart Disease (CHD), Diabetes (DM). Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: China
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective Multicenter Clinical Study：IntracOnary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes

Overview

To evaluate the correlation between maxLCBI4mm/FCTmin(a new index of lipid plaque based on NIRS-OCT technology) and fiber cap thickness , and the prognosis of patients, providing a new quantitative index for early, accurate and comprehensive identification of vulnerable plaques, and exploring preventive measures for adverse events such as cardiac death and recurrent myocardial infarction caused by vulnerable plaques, so as to improve the long-term prognosis of patients.

Primary outcome measures

MACE events in the 24 months after operation [Time frame: 24 months after operation]

Secondary outcome measures (2)

The maxLCBI4mm/FCTmin ratio [Time frame: 24 months after operation]
The maxLCBI4mm/FCTmin ratio [Time frame: 24 months after operation]

Eligibility criteria

Inclusion criteria

18 years old or older, gender is not limited
Patients with diabetes who require an OCT examination or treatment under OCT guidance (diabetes definition: active treatment with insulin or oral hypoglycemic agents at admission). For patients with diabetes who are treated with diet only, abnormal fasting blood sugar (>7 mmol/l), blood sugar >11.1 mmol/l at any time, or abnormal glucose tolerance tests based on World Health Organization standards need to be recorded.
Be able to understand the purpose of clinical research, voluntarily participate can complete the observation as required and sign the informed consent form

5: Lesion stenosis greater than or equal to 50% without interventional treatment

6: The diameter of the blood vessel in the diseased segment is greater than or equal to 2.5 mm

Exclusion criteria

1: Severe coagulation dysfunction (APTT greater than 3 times the upper limit of the normal range)

2: Severe hemodynamic disorder or shock that cannot be corrected

3: Patients with renal impairment（eGFR<30 mL/min/1.73m2）

4: Severe symptoms of heart failure (NYHA III and above) or left ventricular ejection fraction <30%

5: The presence or suspected presence of infective endocarditis or systemic active infection

6: Patients with refractory ventricular arrhythmias who have previously undergone coronary bypass transplantation (CABG) or plan to undergo CABG during the study

7: Patients with serious concurrent diseases such as advanced cancer have a life expectancy of less than 24 months

8: Pregnant or lactating women, have a family plan within 24 months or are unwilling to take effective contraceptive measures

9: The target vessel has severe calcification or severe tortuosity, which cannot be examined by OCT

10: Have participated in other clinical trials or are participating in other drug/device clinical trials within 3 months prior to enrollment and have not met the primary endpoint

11: Investigators believe that those who are unnecessary for OCT or not suitable for inclusion in this trial.

12: There are multiple lesions in the same blood vessel, and the non-target lesion distance requiring treatment vascular segment is less than 5mm

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model: Cohort

Study locations

China · 1 center

Zhongshan Hospital — Shanghai

Identifiers

NCT: NCT06649305 · ORIENT

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗